Nabi Biopharmaceuticals : Positive Interim Results of NicVAX Immunogenicity Study

Jul 23, 2008 - Nabi Biopharmaceuticals (Nasdaq:NABI) announced positive interim results from its Phase 2 NicVAX(r) (Nicotine Conjugate Vaccine) schedule optimization immunogenicity study to assess the antibody response and safety of a 400 microgram, six dose immunization schedule.

Interim results from the study indicate that significantly higher anti-nicotine antibody levels can be generated three months earlier and in a much higher percentage of subjects than observed in previous NicVAX studies. Nabi's new immunization schedule, which included an additional injection at three months, resulted in an immune response at 14 weeks that was higher than the peak antibody level achieved following the six month booster in the Phase 2b proof of concept study. Significantly, the data indicated that more than 80% of subjects achieved the target antibody level at 14 weeks compared to 50% of subjects in the Phase 2b proof of concept study at the same time point. The revised schedule was well tolerated with an adverse event profile comparable to previous NicVAX clinical studies... Nabi Biopharmaceuticals' Press Release -

Nabi Biopharmaceuticals Prevails in Opposition Hearing for NicVAX Patent

April 30, 2008 - Nabi Biopharmaceuticals (Nasdaq:NABI) announced today that the European Patent Office (EPO) upheld the Company's European Patent No. EP 1,135,166 (Hapten Carrier Conjugates for Treating and Preventing Nicotine Addiction) that covers its NicVAX(r) vaccine. The EPO issued this patent to Nabi in late 2004 with an expiration date of January 12, 2019... Nabi Biopharmaceuticals' Press Release -

Nabi Biopharmaceuticals, NicVAX(R) , Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months

Nov. 7, 2007 - ... NicVAX(R) is an innovative and proprietary investigational vaccine being developed by Nabi to treat nicotine addiction and prevent smoking relapse. NicVAX(R) is designed to stimulate the immune system to produce antibodies that bind to nicotine. A nicotine molecule attached to an antibody is too large to cross the blood-brain barrier. Therefore, NicVAX(R) blocks nicotine from reaching its receptors in the brain and prevents the highly-addictive pleasure sensation experienced by smokers and users of nicotine products... Nabi's Press Release -

Nabi Biopharmaceuticals, Positive NicVAX (Nicotine Addiction) Phase 2b Data at Nine Months

Sept. 5 , 2007 - Nabi Biopharmaceuticals (Nasdaq: NABI) today announced nine-month data from its ongoing trial of NicVAX(R) (Nicotine Conjugate Vaccine), the company's innovative and proprietary investigational vaccine being developed to treat nicotine addiction and prevent smoking relapse... Read the Nabi Biopharmaceuticals' Press Release. -